Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen

Archives of Pharmacal Research

Volumn 33, Issue 11, 2010, Pages 1859-1866

  Lee, Young Ran ^a   Lee, Young Hee ^a   Im, Sun A ^a   Yang, In Ho ^a   Ahn, Ghe Whan ^a   Kim, Kyungjae ^b   Lee, Chong Kil ^a  

^a Chungbuk National University   (South Korea)

^b Sahmyook University   (South Korea)

Author keywords

Antigen presentation; CpG; Dendritic cell; Nanoparticle; Opsonization; Poly(I:C)

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; BIODEGRADABILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; OPSONIZATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; CELL PROLIFERATION; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOGLOBULIN G; LACTIC ACID; MICE; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; POLY I-C; POLYGLYCOLIC ACID; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 9;

EID: 78751524107     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-010-1119-z     Document Type: Article

References (34)

1. Diwan, M., Elamanchili, P., Cao, M., and Samuel, J., Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr. Drug Deliv., 1, 405-412 (2004).
2. Elamanchili, P., Diwan, M., Cao, M., and Samuel, J., Char-acterization of poly(D,L-lactic-co-glycolic acid) based nano-particulate system for enhanced delivery of antigens to dendritic cells. Vaccine, 22, 2406-2412 (2004).
3. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C, and Amigorena, S., Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol., 20, 621-667 (2002).
4. Harding, C V., Collins, D. S., Kanagawa, O., and Unanue, E. R., Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J. Immunol., 147, 2860-2863 (1991).
5. He, H., Genovese, K. J., Nisbet, D. J., and Kogut, M. H., Synergy of CpG oligodeoxynucleotide and double-strand-ed RNA (poly I:C) on nitric oxide induction in chicken peri-pheral blood monocytes. Mol. Immunol., 44, 3234-3242 (2007).
6. Hirota, K., Hasegawa, T., Hinata, H., Ito, F., Inagawa, H., Kochi, C., Soma, G., Makino, K., and Terada, H., Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J. Control. Release, 119, 69-76 (2007).
7. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264, 961-965 (1994). (Pubitemid 24196166)
8. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C, and Vogel, J. C., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunosti-mulatory DNA. J. Immunol., 161, 3042-3049 (1998).
9. Kanzler, H., Barrat, F. J., Hessel, E. M., and Coffman, R. L., Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med., 13, 552-559 (2007).
10. Karttunen, J., Sanderson, S., and Shastri, N., Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc. Natl. Acad. Sci. U.S.A., 89, 6020-6024 (1992).
11. Kocbek, P., Obermajer, N., Cegnar, M., Kos, J., and Kristl, J., Targeting cancer cells using PLGA nanoparticles sur-face modified with monoclonal antibody. J. Control. Release, 120, 18-26 (2007).
12. Krieg, A. M., CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol., 20, 709-760 (2002).
13. Kumar, H., Kawai, T., and Akira, S., Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun., 388, 621-625 (2009).
14. Lee, Y. R, Yang, I. H., Lee, Y H., Im, S. A, Song, S, Li, H., Han, K., Kim, K, Eo, S. K, and Lee, C. K, Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restrict-ed antigen presentation pathways in dendritic cells. Blood, 105, 3951-3955 (2005).
15. Lipford, G. B., Sparwasser, T., Bauer, M., Zimmermann, S., Koch, E. S., Heeg, K., and Wagner, H., Immunostimulatory DNA: sequence-dependent production of potentially harm-ful or useful cytokines. Eur. J. Immunol., 27, 3420-3426 (1997).
16. Newman, K. D., Sosnowski, D. L., Kwon, G. S., and Samuel, J., Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J. Pharm. Sci., 87, 1421-1427 (1998).
17. Newman, K. D., Elamanchili, P., Kwon, G. S., and Samuel, J., Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater. Res., 60, 480-486 (2002).
18. Panyam, J. and Labhasetwar, V., Biodegradable nanoparti-cles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 55, 329-347 (2003).
19. Pfeifer, J. D., Wick, M. J., Roberts, R. L., Findlay, K, Normark, S. J., and Harding, C. V., Phagocytic processing of bac-terial antigens for class I MHC presentation to T cells. Nature, 361, 359-362 (1993).
20. Sahoo, S. K., Panyam, J., Prabha, S., and Labhasetwar, V., Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Release, 82, 105-114 (2002).
21. Sellins, K., Fradkin, L., Liggitt, D., and Dow, S., Type I in-terferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. Mol. Ther., 12, 451-459 (2005).
22. Shen, H., Ackerman, A. L., Cody, V., Giodini, A., Hinson, E. R., Cresswell, P., Edelson, R. L., Saltzman, W. M., and Hanlon, D. J., Enhanced and prolonged cross-presenta-tion following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology, 117, 78-88 (2006).
23. Sigal, L. J., Crotty, S., Andino, R., and Rock, K. L., Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature, 398, 77-80 (1999).
24. Sigal, L. J. and Rock, K. L., Bone marrow-derived antigen-presenting cells are required for the generation of cyto-toxic T lymphocyte responses to viruses and use transpor-ter associated with antigen presentation (TAP)-dependent and-independent pathways of antigen presentation. J. Exp. Med., 192, 1143-1150 (2000).
25. Sparwasser, T., Koch, E. S., Vabulas, R. M., Heeg, K, Lipford, G. B., Ellwart, J. W., and Wagner, H., Bacterial DNA and immunostimulatory CpG oligonucleotides trig-ger maturation and activation of murine dendritic cells, Eur. J. Immunol., 28, 2045-2054 (1998).
26. Sparwasser, T., Vabulas, R. M., Villmow, B., Lipford, G. B., and Wagner, H., Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol., 30, 3591-3597 (2000). (Pubitemid 32005232)
27. Stacey, K. J., Sester, D. P., Sweet, M. J., and Hume, D. A., Macrophage activation by immunostimulatory DNA. Curr. Top. Microbiol. Immunol., 247, 41-58 (2000).
28. Tabata, Y. and Ikada, Y., Phagocytosis of polymer micro-spheres by macrophages. Adv. Polym. Sci., 94, 107-141 (1990).
29. Takeda, K., Kaisho, T., and Akira, S., Toll-like receptors, Annu. Rev. Immunol., 21, 335-376 (2003).
30. Venkataprasad, N., Coombes, A. G., Singh, M., Rohde, M., Wilkinson, K., Hudecz, F., Davis, S. S., and Vordermeier, H. M., Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine, 17, 1814-1819 (1999).
31. Weck, M. M., Grunebach, F., Werth, D., Sinzger, C, Bringmann, A., and Brossart, P., TLR ligands differentially affect uptake and presentation of cellular antigens. Blood, 109, 3890-3894 (2007).
32. Weiner, G. J., The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J. Leukoc Biol., 68, 455-463 (2000).
33. Whitmore, M. M., DeVeer, M. J., Edling, A., Oates, R. K., Simons, B., Lindner, D., and Williams, B. R., Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res., 64, 5850-5860 (2004).
34. Zaks, K., Jordan, M., Guth, A., Sellins, K, Kedl, R., Izzo, A., Bosio, C, and Dow, S., Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol., 176, 7335-7345 (2006).